secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K/A
Filed at:   2026-07-16T12:01:18+00:00
Accession:  0001104659-26-084088
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise closes $1.55B sale of sevasemten to Servier; pivots to cardiovascular pipeline
--------------------------------------------------------------------------------

- Received $1.55B upfront cash; eligible for up to $1.1B in regulatory/commercial milestones.
- Pro forma cash at March 31, 2026: $1.53B (up from $33.2M historical).
- Pro forma net income for FY2025: $1.1355B (vs. historical net loss of $167.8M).
- Company now focused on cardiovascular assets EDG-7500, EDG-15400, and EDG-003.
- Transition Services Agreement with Servier: at least 18 months; $17.9M deferred liability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465926084088/0001104659-26-084088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465926084088/tm2620181d2_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-084088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer